Molecule
Peginterferon beta-1a is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. MedsAcross supplies Peginterferon beta-1a for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
PLEGRIDY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. PLEGRIDY is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
Source: US FDA prescribing information
The mechanism by which PLEGRIDY exerts its effects in patients with multiple sclerosis is unknown.
Source: US FDA prescribing information
For subcutaneous or intramuscular use only. Recommended dose: 125 micrograms every 14 days. PLEGRIDY dose should be titrated, starting with 63 micrograms on day 1, 94 micrograms on day 15, and 125 micrograms (full dose) on day 29. A healthcare professional should train patients in the proper technique for self-administering subcutaneous injections using the prefilled pen or syringe or intramuscular injections using the prefilled syringe. Analgesics and/or antipyretics on treatment days may help ameliorate flu-like symptoms
Source: US FDA prescribing information
PLEGRIDY is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta or peginterferon, or any other component of PLEGRIDY. History of hypersensitivity to natural or recombinant interferon beta or peginterferon, or any other component of PLEGRIDY
Source: US FDA prescribing information
Hepatic injury: monitor liver function tests, monitor patients for signs and symptoms of hepatic injury, consider discontinuation of PLEGRIDY if hepatic injury occurs. Depression and suicide: advise patients to report immediately any symptom of depression or suicidal ideation to their healthcare provider, consider discontinuation of PLEGRIDY if depression occurs. Anaphylaxis and other allergic reactions: Discontinue PLEGRIDY if a serious allergic reaction occurs. Injection site reactions: Do not administer PLEGRIDY into affected area until fully healed, if multiple lesions occur, change injection site or discontinue PLEGRIDY until healing of skin lesions. Congestive heart failure: monitor patients with pre-existing significant cardiac disease for worsening of cardiac symptoms. Decreased peripheral blood counts: monitor complete blood counts.
Source: US FDA prescribing information
The following serious adverse reactions are discussed in more detail in other sections of labeling: Hepatic Injury Depression and Suicide Anaphylaxis and Other Allergic Reactions Injection Site Reactions Including Necrosis Congestive Heart Failure Decreased Peripheral Blood Counts Thrombotic Microangiopathy Pulmonary Arterial Hypertension Autoimmune Disorders Seizures The most common adverse reactions in clinical trials of subcutaneous PLEGRIDY (incidence ≥10% and at least 2% more frequent on PLEGRIDY than on placebo) were injection site erythema, influenza-like illness, pyrexia, headache, myalgia, chills, injection site pain, asthenia, injection site pruritus, and arthralgia or http://www.fda.gov/medwatch.
Source: US FDA prescribing information
Store PLEGRIDY prefilled pens and prefilled syringes in a refrigerator between 2°C to 8°C (36°F to 46°F) in the closed original carton to protect from light until ready for injection. Do not freeze. If refrigeration is unavailable, PLEGRIDY may be stored at room temperature up to 25°C (77°F) for a period up to 30 days, protected from light. PLEGRIDY can be removed from, and returned to, a refrigerator if necessary. The total combined time out of refrigeration should not exceed 30 days.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
5 presentations of Peginterferon beta-1a, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Plegridy kitSubcutaneous Cold chain | Biogen | US FDA | Available on request |
| Plegridy 125 mcg/0.5 mL injectionIntramuscular Cold chain | Biogen | US FDA | Available on request |
| Plegridy 125 mcg/0.5 mL injectionSubcutaneous Cold chain | Biogen | US FDA | Available on request |
| Plegridy Pen kitSubcutaneous Cold chain | Biogen | US FDA | Available on request |
| Plegridy Pen 125 mcg/0.5 mL injectionSubcutaneous Cold chain | Biogen | US FDA | Available on request |
2 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 5 presentations of Peginterferon beta-1a and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 2 brand names for Peginterferon beta-1a, including Plegridy, Plegridy Pen.
Yes. The US FDA first approved Peginterferon beta-1a on 15 August 2014, according to Drugs@FDA.
Yes. Peginterferon beta-1a has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Peginterferon beta-1a must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Peginterferon beta-1a is classified under ATC code L03AB13 (Peginterferon beta-1a).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.